BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32323451)

  • 1. Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects.
    Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Yabe D; Inagaki N
    J Diabetes Investig; 2020 Nov; 11(6):1448-1456. PubMed ID: 32323451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Treatment with Bone Marrow-Derived Mesenchymal Stem Cells and Exendin-4 Promotes Islet Regeneration in Streptozotocin-Induced Diabetic Rats.
    Song X; Sun X; Hao H; Han Q; Han W; Mu Y
    Stem Cells Dev; 2021 May; 30(9):502-514. PubMed ID: 33677993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents.
    Mietlicki-Baase EG; Liberini CG; Workinger JL; Bonaccorso RL; Borner T; Reiner DJ; Koch-Laskowski K; McGrath LE; Lhamo R; Stein LM; De Jonghe BC; Holz GG; Roth CL; Doyle RP; Hayes MR
    Diabetes Obes Metab; 2018 May; 20(5):1223-1234. PubMed ID: 29327400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
    Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
    Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
    Brown JD; McAnally D; Ayala JE; Burmeister MA; Morfa C; Smith L; Ayala JE
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R595-R608. PubMed ID: 29949410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel radioiodinated exendin-4 derivatives targeting GLP-1 receptor for detection of β-cell mass.
    Ogawa Y; Kimura H; Fujimoto H; Kawashima H; Toyoda K; Mukai E; Yagi Y; Ono M; Inagaki N; Saji H
    Bioorg Med Chem; 2021 Dec; 52():116496. PubMed ID: 34808404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
    Mann RJ; Nasr NE; Sinfield JK; Paci E; Donnelly D
    Br J Pharmacol; 2010 Aug; 160(8):1973-84. PubMed ID: 20649595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonist exendin 4 ameliorates diabetes-associated vascular calcification by regulating mitophagy through the AMPK signaling pathway.
    Chen K; Jin HJ; Wu ZH; Zhang BF; Wu J; Huang ZY; Huang YP; Lu XW; Zheng XT
    Mol Med; 2024 May; 30(1):58. PubMed ID: 38720283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
    Zhong X; Chen Z; Chen Q; Zhao W; Chen Z
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30795583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirectly radioiodinated exendin-4 as an analytical tool for in vivo detection of glucagon-like peptide-1 receptor in a disease setting.
    Kondo N; Oishi A; Hirata M; Temma T
    Ann Nucl Med; 2021 Jan; 35(1):83-91. PubMed ID: 33067731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1).
    Ang R; Mastitskaya S; Hosford PS; Basalay M; Specterman M; Aziz Q; Li Y; Orini M; Taggart P; Lambiase PD; Gourine A; Tinker A; Gourine AV
    Circ Arrhythm Electrophysiol; 2018 Oct; 11(10):e006740. PubMed ID: 30354404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of glucagon-like peptide-1 receptors and skilled reach foraging.
    Vestlund J; Bergquist F; Licheri V; Adermark L; Jerlhag E
    Addict Biol; 2021 May; 26(3):e12953. PubMed ID: 32770792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4.
    Tinsley IC; Borner T; Swanson ML; Chepurny OG; Doebley SA; Kamat V; Sweet IR; Holz GG; Hayes MR; De Jonghe BC; Doyle RP
    J Med Chem; 2021 Mar; 64(6):3479-3492. PubMed ID: 33677970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effect of GABA and glucagon-like peptide-1 receptor agonist on cytokine-induced apoptosis in pancreatic β-cell line and isolated human islets.
    Son DO; Liu W; Li X; Prud'homme GJ; Wang Q
    J Diabetes; 2019 Jul; 11(7):563-572. PubMed ID: 30520247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exendin-4 modulates diabetes onset in nonobese diabetic mice.
    Hadjiyanni I; Baggio LL; Poussier P; Drucker DJ
    Endocrinology; 2008 Mar; 149(3):1338-49. PubMed ID: 18063685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
    Koike M; Saito H; Kohno G; Takubo M; Watanabe K; Ishihara H
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 peptide analogs for targeting pancreatic beta cells.
    Alavi SE; Ebrahimi Shahmabadi H
    Drug Discov Today; 2021 Aug; 26(8):1936-1943. PubMed ID: 33839290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.
    Gaborit B; Julla JB; Besbes S; Proust M; Vincentelli C; Alos B; Ancel P; Alzaid F; Garcia R; Mailly P; Sabatier F; Righini M; Gascon P; Matonti F; Houssays M; Goumidi L; Vignaud L; Guillonneau X; Erginay A; Dupas B; Marie-Louise J; Autié M; Vidal-Trecan T; Riveline JP; Venteclef N; Massin P; Muller L; Dutour A; Gautier JF; Germain S
    J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31589290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
    Perry RA; Craig SL; Gault VA; Flatt PR; Irwin N
    Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34370015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs.
    Bornebusch AB; Fink-Jensen A; Wörtwein G; Seeley RJ; Thomsen M
    eNeuro; 2019; 6(2):. PubMed ID: 31058214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.